Clinical Impact and Safety Profile of Intravenous Lacosamide Administration as Adjunctive Therapy for Neonatal...

Area of Science:

• Neonatal Neurology
• Clinical Pharmacology

Background:

• Neonatal seizures, particularly refractory cases, present significant clinical challenges.
• Limited treatment options exist for symptomatic refractory seizures in newborns.

Purpose of the Study:

• To evaluate the clinical efficacy and safety of lacosamide in neonates with symptomatic refractory seizures.
• To assess the long-term outcomes and tolerance of lacosamide treatment up to 24 months of age.

Main Methods:

• Retrospective descriptive study of eight neonates with symptomatic refractory seizures.
• Lacosamide administered as third- or fourth-line therapy; data collected on dosage, duration, concurrent treatments, and adverse events.

Main Results:

• 62.5% of patients achieved complete seizure remission after lacosamide loading dose.
• Remaining patients experienced a reduction in seizure frequency.
• No adverse effects attributable to lacosamide were reported during the follow-up period.

Conclusions:

• Lacosamide demonstrates potential efficacy in achieving seizure remission in newborns with refractory seizures.
• Lacosamide exhibits excellent tolerance in the neonatal population.
• Further randomized controlled trials are warranted to confirm these preliminary findings.